Abstract
Objective: The prognostic value of the mutation types and dynamics of FLT3‐ITD in acute myeloid leukemia (AML) and other known factors were studied.Methods: Initial and follow‐up samples from 45 AML patients with FLT3‐ITD mutations were analyzed by fragment length analysis, Sanger sequencing, and next‐generation sequencing.Results: Some patients (13%) had multiple FLT3‐ITD mutations, and many of them had acute promyelocytic leukemia (APL). FLT3‐ITD mutations were classified according to mutation types, including duplication‐only FLT3‐ITD (52%) and FLT3‐ITD with duplications and insertions (dup + ins) (48%). The dup + ins FLT3‐ITD variant was independently associated with poor prognosis among non‐APL patients (odds ratio, 2.92) in addition to FLT3‐ITD with ≥50% variant allele frequency (VAF). The VAFs of FLT3‐ITD were low (median 2.2%) when detected during morphologic complete remission (CR) after conventional chemotherapy; however, in two patients treated with gilteritinib after relapse, the VAFs of FLT3‐ITD were much higher (>95% and 8.1%) in the morphologic CR state.Conclusions: The type of FLT3‐ITD mutation is important in prognosis, and the dup + ins type of FLT3‐ITD can be an indicator of poor prognosis. In addition, the FLT3‐ITD mutation status may unexpectedly not match the morphologic examination results after gilteritinib treatment.
Funding Information
  • Ministry of Education (NRF‐2020R1I1A3A04037773)

This publication has 36 references indexed in Scilit: